Calamos Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Calamos Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-98,000	Closed	-$6.08M	–	915
2020 Q4	$6.08M	Buy	+98,000	New	+$6.03M	0.04%	453

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Calamos Advisors's BMY Position: Q2 2026 in Review

Calamos Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 8,629 shares — an estimated $523K sold.

Calamos Advisors first reported a position in BMY in Q2 2013 and held it in 49 quarters. The position peaked at $95.4M in Q2 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Calamos Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
Calamos Advisors sold 8,629 Bristol-Myers Squibb shares in Q2 2026, an estimated $523K.
Calamos Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 49 quarters.
Calamos Advisors's Bristol-Myers Squibb position peaked at $95.4M in Q2 2022.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.